Skip to main content
Top
Published in: Breast Cancer 2/2008

01-04-2008 | Case Report

Two cases of occult breast cancer in which PET-CT was helpful in identifying primary tumors

Authors: Daisuke Takabatake, Naruto Taira, Kenjiro Aogi, Shozo Ohsumi, Shigemitsu Takashima, Takeshi Inoue, Rieko Nishimura

Published in: Breast Cancer | Issue 2/2008

Login to get access

Abstract

We report two cases of occult breast cancer in which masses were completely nonpalpable and positron emission tomography-computed tomography (PET-CT) was extremely helpful in identifying the primary tumor. Case 1 involved a 56-year-old woman with enlarged lymph nodes 3 cm in size in the axilla. Based on excisional biopsy, axillary lymph node metastasis of breast cancer was suspected but an obvious primary tumor in the breast was not identifiable on mammography, contrast-enhanced CT, or ultrasonography. Faint accumulation of fluorodeoxyglucose (FDG) was noted only on PET-CT, so the site was considered to be the primary site, and operation was performed. As a result of postoperative pathological examination, ductal carcinoma in-situ (DCIS) was diagnosed. Case 2 involved a 55-year-old woman with enlarged lymph nodes 3 cm in size in the axilla. Based on the excisional biopsy, axillary lymph node metastasis of breast cancer was suspected. In this case as well, an obvious primary tumor was not identifiable with palpation or mammography. On PET-CT, faint accumulation of FDG was noted in the vicinity of the CD regions, or upper and lower outer quadrants. When contrast-enhanced CT and ultrasonography were performed, a faint nodular opacity less than 1 cm in size corresponding to this site was found and diagnosed as the primary site, operation was subsequently performed. Pathologic diagnosis indicated invasive cancer. PET-CT is a helpful option for the diagnosis of occult breast cancer with primary sites that conventional imaging studies have difficulty identifying.
Literature
1.
go back to reference Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125(2):210–4.PubMed Baron PL, Moore MP, Kinne DW, Candela FC, Osborne MP, Petrek JA. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125(2):210–4.PubMed
2.
go back to reference Dockerty MB, Gray HK, Pierce EH. Surgical significance of isolated axillary adenopathy. Ann Surg. 1957;145(1):104–7.PubMedCrossRef Dockerty MB, Gray HK, Pierce EH. Surgical significance of isolated axillary adenopathy. Ann Surg. 1957;145(1):104–7.PubMedCrossRef
3.
go back to reference Kemeny MM, Rivera DE, Terz JJ, Benfield JR. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152(1):43–7.PubMedCrossRef Kemeny MM, Rivera DE, Terz JJ, Benfield JR. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152(1):43–7.PubMedCrossRef
4.
go back to reference Morris EA, Schwartz LH, Dershaw DD, van Zee KJ, Abramson AF, Liberman L. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology. 1997;205(2):437–40.PubMed Morris EA, Schwartz LH, Dershaw DD, van Zee KJ, Abramson AF, Liberman L. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology. 1997;205(2):437–40.PubMed
5.
go back to reference Orel SG, Mendonca MH, Reynolds C, Schnall MD, Solin LJ, Sullivan DC. MR imaging of ductal carcinoma in situ. Radiology. 1997;202(2): 413–20.PubMed Orel SG, Mendonca MH, Reynolds C, Schnall MD, Solin LJ, Sullivan DC. MR imaging of ductal carcinoma in situ. Radiology. 1997;202(2): 413–20.PubMed
6.
go back to reference Tilanus-Linthorst MM, Obdeijn AI, Bontenbal M, Oudkerk M. MRI in patients with axillary metastases of occult breast carcinoma. Breast Cancer Res Treat. 1997;44(2):179–82.PubMedCrossRef Tilanus-Linthorst MM, Obdeijn AI, Bontenbal M, Oudkerk M. MRI in patients with axillary metastases of occult breast carcinoma. Breast Cancer Res Treat. 1997;44(2):179–82.PubMedCrossRef
7.
go back to reference Olson JA Jr, Morris EA, Van Zee KJ, Linehan DC, Borgen PI. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000;7(6):411–5.PubMedCrossRef Olson JA Jr, Morris EA, Van Zee KJ, Linehan DC, Borgen PI. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000;7(6):411–5.PubMedCrossRef
8.
go back to reference Akashi-Tanaka S, Fukutomi T, Miyakawa K, Uchiyama N, Nanasawa T, Tsuda H. Contrast-enhanced computed tomography detection of occult breast cancers presenting as axillary masses. Breast Cancer Res Treat. 1999;55(1):97–101.PubMedCrossRef Akashi-Tanaka S, Fukutomi T, Miyakawa K, Uchiyama N, Nanasawa T, Tsuda H. Contrast-enhanced computed tomography detection of occult breast cancers presenting as axillary masses. Breast Cancer Res Treat. 1999;55(1):97–101.PubMedCrossRef
9.
go back to reference Block EF, Meyer MA. Positron emission tomography in diagnosis of occult adenocarcinoma of the breast. Am Surg. 1998;64(9):906–8.PubMed Block EF, Meyer MA. Positron emission tomography in diagnosis of occult adenocarcinoma of the breast. Am Surg. 1998;64(9):906–8.PubMed
10.
go back to reference Scoggins CR, Vitola JV, Sandler MP, Atkinson JB, Frexes-Steed M. Occult breast carcinoma presenting as an axillary mass. Am Surg. 1999;65(1):1–5.PubMed Scoggins CR, Vitola JV, Sandler MP, Atkinson JB, Frexes-Steed M. Occult breast carcinoma presenting as an axillary mass. Am Surg. 1999;65(1):1–5.PubMed
11.
go back to reference van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van Geldere D, et al. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg. 2002;236(5):619–24.PubMedCrossRef van der Hoeven JJ, Hoekstra OS, Comans EF, Pijpers R, Boom RP, van Geldere D, et al. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg. 2002;236(5):619–24.PubMedCrossRef
12.
go back to reference Avril N, Rose CA, Scelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Scwaiger M. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and Limitation. J Clin Oncol. 2000;18:3495–502.PubMed Avril N, Rose CA, Scelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Scwaiger M. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and Limitation. J Clin Oncol. 2000;18:3495–502.PubMed
13.
go back to reference Owaki T, Kijima Y, Yoshinaka H, Uenosono Y, Yoshioka T, Natsugoe S, Aikou T. Ductal carcinoma in-situ of the breast detected by [F-18] fluorodeoxyglucose positron emission tomography. Breast Cancer. 2006;13:210–3.PubMedCrossRef Owaki T, Kijima Y, Yoshinaka H, Uenosono Y, Yoshioka T, Natsugoe S, Aikou T. Ductal carcinoma in-situ of the breast detected by [F-18] fluorodeoxyglucose positron emission tomography. Breast Cancer. 2006;13:210–3.PubMedCrossRef
14.
go back to reference Walter C, Scheidhauer K, Scharl A, Goering UJ, Theissen P, Kugel H, et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur Radiol. 2003;13:1651–6.PubMedCrossRef Walter C, Scheidhauer K, Scharl A, Goering UJ, Theissen P, Kugel H, et al. Clinical and diagnostic value of preoperative MR mammography and FDG-PET in suspicious breast lesions. Eur Radiol. 2003;13:1651–6.PubMedCrossRef
Metadata
Title
Two cases of occult breast cancer in which PET-CT was helpful in identifying primary tumors
Authors
Daisuke Takabatake
Naruto Taira
Kenjiro Aogi
Shozo Ohsumi
Shigemitsu Takashima
Takeshi Inoue
Rieko Nishimura
Publication date
01-04-2008
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2008
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-007-0027-7

Other articles of this Issue 2/2008

Breast Cancer 2/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine